LINEAGE CELL THERAPEUTICS IN (LCTX) Stock Price & Overview
NYSEARCA:LCTX • US53566P1093
Current stock price
The current stock price of LCTX is 1.565 USD. Today LCTX is down by -1.57%. In the past month the price decreased by -18.46%. In the past year, price increased by 267.72%.
LCTX Key Statistics
- Market Cap
- 389.826M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.22
- Dividend Yield
- N/A
LCTX Stock Performance
LCTX Stock Chart
LCTX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to LCTX. When comparing the yearly performance of all stocks, LCTX is one of the better performing stocks in the market, outperforming 97.21% of all stocks.
LCTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LCTX. The financial health of LCTX is average, but there are quite some concerns on its profitability.
LCTX Earnings
LCTX Forecast & Estimates
13 analysts have analysed LCTX and the average price target is 5.1 USD. This implies a price increase of 225.88% is expected in the next year compared to the current price of 1.565.
For the next year, analysts expect an EPS growth of 70.33% and a revenue growth 124.49% for LCTX
LCTX Groups
Sector & Classification
LCTX Financial Highlights
Over the last trailing twelve months LCTX reported a non-GAAP Earnings per Share(EPS) of -0.22. The EPS decreased by -120% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.43% | ||
| ROE | -142.61% | ||
| Debt/Equity | 0 |
LCTX Ownership
LCTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.09 | 380.121B | ||
| AMGN | AMGEN INC | 15.19 | 190.443B | ||
| GILD | GILEAD SCIENCES INC | 15.73 | 174.171B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.61 | 113.617B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.1 | 82.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.53 | 43.596B | ||
| INSM | INSMED INC | N/A | 35.536B | ||
| NTRA | NATERA INC | N/A | 28.801B | ||
| BIIB | BIOGEN INC | 11.02 | 26.972B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.84 | 24.995B | ||
| MRNA | MODERNA INC | N/A | 19.759B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.548B | ||
| INCY | INCYTE CORP | 12.43 | 18.767B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LCTX
Company Profile
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 72 full-time employees. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, it designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
Company Info
IPO: 1992-03-05
LINEAGE CELL THERAPEUTICS IN
2173 Salk Avenue, Suite 200
Carlsbad CALIFORNIA 92008 US
CEO: Brian M. Culley
Employees: 72
Phone: 15105213390
LINEAGE CELL THERAPEUTICS IN / LCTX FAQ
What does LCTX do?
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 72 full-time employees. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, it designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
What is the current price of LCTX stock?
The current stock price of LCTX is 1.565 USD. The price decreased by -1.57% in the last trading session.
Does LINEAGE CELL THERAPEUTICS IN pay dividends?
LCTX does not pay a dividend.
How is the ChartMill rating for LINEAGE CELL THERAPEUTICS IN?
LCTX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
When does LINEAGE CELL THERAPEUTICS IN (LCTX) report earnings?
LINEAGE CELL THERAPEUTICS IN (LCTX) will report earnings on 2026-05-11.
Who owns LINEAGE CELL THERAPEUTICS IN?
You can find the ownership structure of LINEAGE CELL THERAPEUTICS IN (LCTX) on the Ownership tab.
What is the outstanding short interest for LINEAGE CELL THERAPEUTICS IN?
The outstanding short interest for LINEAGE CELL THERAPEUTICS IN (LCTX) is 10.76% of its float.